98%
921
2 minutes
20
Human METCAM/MUC18, a cell adhesion molecule (CAM) in the immunoglobulin-like gene super family, plays a dual role in the progression of several epithelium cancers; however, its role in the nasopharyngeal carcinoma (NPC) remains unclear. To initiate the study we determined human METCAM/MUC18 expression in tissue samples of normal nasopharynx (NP), NPCs, and metastatic lesions, and in two established NPC cell lines. Immunoblotting analysis was used for the determination in lysates of frozen tissues, and immunohistochemistry (IHC) for expression in formalin-fixed, paraffin-embedded tissue sections of 7 normal nasopharynx specimens, 94 NPC tissue specimens, and 3 metastatic lesions. Human METCAM/MUC18 was expressed in 100% of the normal NP, not expressed in 73% of NPC specimens (or expressed at very low levels in only about 27% of NPC specimens), and expressed again in all of the metastatic lesions. The level of human METCAM/MUC18 expression in NPC tissues was about one fifth of that in the normal NP and metastatic lesions. The low level of human METCAM/ MUC18 expression in NPC specimens was confirmed by a weak signal of RT-PCR amplification of the mRNA. Low expression levels of human METCAM/MUC18 in NPC tissues were also reflected in the seven established NPC cell lines. These findings provided the first evidence that diminished expression of human METCAM/MUC18 is an indicator for the emergence of NPC, but increased expression then occurs with metastatic progression, suggesting that huMETCAM/MUC18, perhaps similar to TGF-β, may be a tumor suppressor, but a metastasis promoter for NPC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7314/apjcp.2014.15.1.245 | DOI Listing |
Asian Pac J Cancer Prev
August 2025
Biochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.
Background: METCAM/MUC18 may be a new serum biomarker for predicting malignant propensity of prostate cancer by using a modified lateral flow immune assay (modified LFIA), which used the extremely high affinity between biotin and streptavidin and two antibody combinations to increase the sensitivity and specificity of traditional LFIA. To increase the sensitivity and specificity to the highest degree, in this report we further improved this modified LFIA by using a new antibody combination, which includes a biotinylated home-made chicken antibody and a nano-gold conjugated rabbit antibody (MBS416853).
Materials And Methods: A calibration curve was established from two recombinant METCAM/MUC18 proteins (C-terminus GST as the positive control and NM-GST the negative control) and used for determining METCAM/MUC18 concentrations in 36 serum specimens from normal individuals and patients of benign prostatic hypertrophy (BPH) patients, prostatic intraepithelial neoplasia (PIN), and prostate cancer at various Gleason scores and after treatment.
Int J Mol Sci
November 2022
Department of Bioscience Technology, Chung Yuan Christian University, Chung Li District, Taoyuan City 32023, Taiwan.
From previous studies of negatively correlating the expression of human METCAM/MUC18 with the pathology of nasopharyngeal carcinoma (NPC), we have suggested that human METCAM/MUC18 (huMETCAM/MUC18) might play a tumor suppressor role in the development of nasopharyngeal carcinoma. To scrutinize this hypothesis, we investigated the effects of huMETCAM/MUC18's over-expression on in vitro cellular behavior and on the in vivo tumorigenesis of one NPC cell line (NPC-TW01). HuMETCAM/MUC18 cDNA was first transfected into the NPC-TW01 cell line, which was established from NPC type I, and many G418-resistant clones were obtained.
View Article and Find Full Text PDFAdv Exp Med Biol
August 2021
Department of Microbiology & Immunology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Objectives: We tested if METCAM/MUC18 overexpression also plays a suppressor role in another human ovarian cancer cell line, BG-1, in addition to the SK-OV3 cell line.
Methods: Human ovarian cancer BG-1 cells were transfected with METCAM/MUC18 cDNA and G418-resistant clones expressing different levels of METCAM/MUC18 were isolated. These clones were used to test the effects of enforced expression of METCAM/MUC18 on in vitro motility, invasiveness, and anchorage-independent colony formation (in vitro tumorigenesis), and in vivo tumorigenesis after SC injection and after IP injection in female athymic nude mice.
Diagnostics (Basel)
March 2021
Cancer Metastasis Laboratory, Department of Bioscience Technology, Chung Yuan Christian University, Chung-li District, Taoyuan City 32023, Taiwan.
(1) Background: To further validate METCAM/MUC18 as a diagnostic biomarker for prostate cancer, a modified Lateral Flow Immune Assay (LFIA) with increased sensitivity and specificity was designed by taking advantage of the extremely high affinity between biotin and streptavidin and used. (2) Methods: The combination of a commercial biotinylated rabbit antibody (EPP11278), or the home-made biotinylated chicken antibody, and the nano-gold conjugated home-made chicken antibody or a commercial rabbit antibody (EPP11278), had the higher sensitivity and specificity in this modified LFIA to establish calibration curves from the two recombinant METCAM/MUC18 proteins and were used for determining METCAM/MUC18 concentrations in serum specimens from normal individuals, benign prostatic hyperplasia (BPH) patients, prostatic intraepithelial neoplasia (PIN) patients, prostate cancer patients with various Gleason scores, and treated patients. (3) Results: Data obtained by this modified LFIA were statistically better than traditional LFIA and prostate-specific antigen (PSA) test.
View Article and Find Full Text PDFCancer Biomark
November 2020
Cancer Metastasis Laboratory, Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li, Taoyuan, Taiwan.
Background: METCAM/MUC18 expression was increased with the malignant progression of prostate cancer and also a bona fide metastatic gene, capable of initiating and driving the metastasis of a non-metastatic human prostate cancer cell line to multiple organs.
Objective: We explored if METCAM/MUC18 was detectable in human serum and a novel biomarker to predict malignant propensity of prostate cancer.
Materials And Methods: Two antibodies were identified by Western blot analysis having the highest sensitivity and specificity to establish calibration curves from the recombinant METCAM/MUC18 proteins.